MYK-224 by Bristol-Myers Squibb for Diastolic Heart Failure (HFpEF): Likelihood of Approval

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

Feb 16, 2024 - 18:00

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

Read the original article

Tags:

Previous Article

Psychedelic treatments for mental health: Is there substance behind the hype?

Trial for Gritstone’s BARDA-funded COVID-19 vaccine delayed due to production is...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Pfizer launches digital healthcare platform to streamline access

Pfizer launches digital healthcare platform to streamli...

Aug 29, 2024

STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation

STAT+: Teladoc stock slides despite business growth, Me...

Oct 26, 2023

The changing of the guard is expected in the Crohn’s disease marketplace

The changing of the guard is expected in the Crohn’s di...

Sep 1, 2023